Eligibility for expanded access typically requires that the patient has a serious or immediately life-threatening condition, such as advanced stage cancer. Additionally, the patient must have no other satisfactory treatment options and must not be eligible to participate in a clinical trial. The treating physician also needs to determine that the potential benefit justifies the potential risks of the investigational therapy.
